Ponatinib (AP24534) inhibits MEKK3-KLF signaling and prevents formation and progression of cerebral cavernous malformations - Choi, J. P., Wang, R., Yang, X., Wang, X., Wang, L., Ting, K. K., Foley, M., Cogger, V., Yang, Z., Liu, F., Han, Z., Liu, R., Baell, J., Zheng, X. (American Association for the Advancement of Science (AAAS), 2018)
6354932